Prof Jean-Marc Classe speaks to ecancer at ASCO 2024 about the results from the CARACO phase III randomised trial.

This trial evaluated the omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy.

He reports that there is no difference in PFS and OS between lymphadenectomy and no lymphadenectomy.

Prof Classe believes that we can now conclude that for these patients you can avoid the morbidity, pain and duration of surgery.